University of Pennsylvania Division of Hematology Oncology Perelman Center for Advanced Medicine
Philadelphia, Pennsylvania, United States
Medical center in Philadelphia, Pennsylvania
3400 Civic Center Blvd, Philadelphia, PA 19104
About University of Pennsylvania Division of Hematology Oncology Perelman Center for Advanced Medicine
The Ruth and Raymond Perelman Center for Advanced Medicine is a specialized medical facility located at 34th Street and Civic Center Boulevard, on the former site of the Philadelphia Civic Center, on the campus of the Hospital of the University of Pennsylvania.
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Clinical Trials at University of Pennsylvania Division of Hematology Oncology Perelman Center for Advanced Medicine
During the past decade, University of Pennsylvania Division of Hematology Oncology Perelman Center for Advanced Medicine conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 0 clinical trials were completed, i.e. on
average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 0 clinical trials were completed. i.e. 0%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Adefovir or Entecavir in Patients With HBeAg-Positive Chronic Hepatitis B
2010-05-07
2014-09-29
Completed
280
A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer
2009-10-16
2017-01-24
Completed
596
A Study of Tarceva (Erlotinib) as First Line Therapy in Participants With Non-Small Cell Lung Cancer Harbouring Epidermal Growth Factor Receptor (EGFR) Mutations
2011-04-30
2016-12-30
Completed
208
A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer
2011-11-08
2028-11-30
Active, not recruiting
4,804
A Study to Collect Blood Biomarker Samples From Participants With Chronic Hepatitis B (CHB) Who Received Treatment With Pegasys (Peginterferon Alfa-2a) ± Nucleoside/Nucleotide Analogue
2013-08-20
2014-11-28
Completed
1,669
A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer
2014-01-31
2021-06-04
Completed
1,846
A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy
2016-09-26
2020-02-06
Completed
202
A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)
2017-03-29
2019-06-11
Terminated
806
Clinical Trials Sponsors and Collaborators
Clinical Trials Conditions at University of Pennsylvania Division of Hematology Oncology Perelman Center for Advanced Medicine
According to Clinical.Site data, the most researched conditions in "University of Pennsylvania Division of Hematology Oncology Perelman Center for Advanced Medicine" are
"Advanced or Metastatic Non-small Cell Lung Cancer" (1 trials), "Carcinoma, Non-Small-Cell Lung" (1 trials) and "Non-Small-Cell Lung Cancer" (1 trials). Many other conditions were trialed in "University of Pennsylvania Division of Hematology Oncology Perelman Center for Advanced Medicine" in a lesser frequency.
Clinical Trials Intervention Types at University of Pennsylvania Division of Hematology Oncology Perelman Center for Advanced Medicine
Most popular intervention types in "University of Pennsylvania Division of Hematology Oncology Perelman Center for Advanced Medicine" are "Drug" (3 trials). Other intervention types were less common.
The name of intervention was led by "Lazertinib" (3 trials), "Amivantamab" (2 trials), "Carboplatin" (2 trials), "Pemetrexed" (2 trials) and "Amivantamab Intravenous" (1 trials). Other intervention names were less common.
Clinical Trials Genders at University of Pennsylvania Division of Hematology Oncology Perelman Center for Advanced Medicine
The vast majority of trials in "University of Pennsylvania Division of Hematology Oncology Perelman Center for Advanced Medicine" are
3 trials for "All" genders.
Clinical Trials Status at University of Pennsylvania Division of Hematology Oncology Perelman Center for Advanced Medicine
Currently, there are NaN active trials in "University of Pennsylvania Division of Hematology Oncology Perelman Center for Advanced Medicine".
undefined are not yet recruiting,
3 are recruiting,
undefined are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were undefined completed trials in University of Pennsylvania Division of Hematology Oncology Perelman Center for Advanced Medicine,
undefined suspended trials,
and undefined terminated clinical trials to date.
Out of the total trials that were conducted in University of Pennsylvania Division of Hematology Oncology Perelman Center for Advanced Medicine, 2 "Phase 1"
clinical trials were conducted, 0 "Phase 2" clinical
trials and 1 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".